Community-Acquired Pneumonia Treatment with Levofloxacin

Recommended Dosing Regimens

The Infectious Diseases Society of America recommends levofloxacin 750 mg IV or orally once daily for 5 days as the preferred respiratory fluoroquinolone monotherapy regimen for hospitalized non-ICU patients with community-acquired pneumonia, providing equivalent efficacy to the traditional 500 mg daily for 7-10 days with improved pharmacodynamic optimization 1, 2
The American Thoracic Society guidelines suggest that levofloxacin 500 mg IV or orally once daily for 7-14 days remains an acceptable alternative, particularly for severe CAP or when specific pathogens require extended therapy 3, 1

For outpatient CAP with comorbidities, the IDSA recommends levofloxacin 750 mg orally once daily for 5 days as monotherapy, with strong recommendation and high-quality evidence 1, 2
For hospitalized non-ICU patients, the IDSA recommends levofloxacin 750 mg IV or orally once daily for 5 days as monotherapy, with strong recommendation and Level I evidence 1, 2

Levofloxacin provides comprehensive coverage for typical CAP pathogens, including S. pneumoniae (including MDRSP), H. influenzae, M. catarrhalis, K. pneumoniae, and methicillin-susceptible S. aureus 1
For Gram-negative enteric bacilli pneumonia, the British Thoracic Society guidelines recommend extending the duration of levofloxacin to 14-21 days, regardless of clinical improvement 3, 4

The IDSA recommends a minimum of 5 days of levofloxacin therapy for uncomplicated CAP, continuing until afebrile for 48-72 hours with no more than one sign of clinical instability 1, 2
The standard duration of levofloxacin therapy is 5-7 days for most cases of CAP once clinical stability is achieved 1, 2

The IDSA recommends avoiding fluoroquinolone monotherapy indiscriminately for outpatient CAP and reserving it for patients with specific contraindications to β-lactams/macrolides or documented resistance patterns 3, 1, 2
The IDSA also recommends avoiding macrolide monotherapy in areas where pneumococcal macrolide resistance exceeds 25% and using levofloxacin as the preferred alternative in these settings 1, 2